'Wonder Woman' Gal Gadot Opens Up About Rare, Life-Threatening Complication During Pregnancy, Reminds Women To Trust Their Instincts

“Women experience this complication most often in their third trimester due to bodily changes that make them more likely to develop blood clots as a protective mechanism against excessive bleeding ...

Trendy supplement that claims to build muscle and boost brain power linked to deadly blood clots

CREATINE has spent decades hiding in the gym, enhancing the workouts of bodybuilders and athletes. But the supplement is now ...
Fierce Pharma

BMS, J&J factor in HCP education on clot-busting mechanism before milvexian data drop

Ahead of the readouts, BMS and J&J have started an educational push called “Change the Target. Change What’s Possible,” they announced Tuesday. The campaign is designed to inform clinicians who manage ...

SonoVascular Completes First Close of Series A Preferred Stock Financing

SonoVascular, Inc., a clinical stage medical device company focused on transforming the treatment of venous thromboembolism (VTE) with its SonoThrombectomy(TM) System, has completed the first close of ...
Le Lézard

FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need

Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the company's supplemental Biologics License Application (sBLA) for HYMPAVZI® ...
PharmTech

FDA Grants Priority Review For Pfizer’s Marstacimab for Hemophilia A or B

FDA priority review seeks marstacimab label expansion to ≥6 years with inhibitors and ages 6–11 without inhibitors, addressing populations with limited efficacy from factor replacement and high unmet ...
The American Journal of Managed Care

Stroke Subtype Does Not Affect Efficacy of Asundexian for Second Stroke Prevention

Global phase 3 OCEANIC-STROKE randomized 12,327 patients to asundexian 50 mg daily vs placebo on background antiplatelets, with follow-up to 31 months. Treatment effects were consistent across TOAST ...
Medscape

First Clear Win for Factor XIa Inhibitors in Stroke With Reduced Recurrence, No Increased Bleeding Risk

The factor XIa inhibitor asundexian reduced recurrent ischemic stroke without increasing major or minor bleeding in patients ...

Cereno Scientific broadens development focus for CS014 to pulmonary hypertension associated with interstitial lung disease

Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with ...
Mirage News

FDA Fast-Tracks HYMPAVZI for Hemophilia & B Treatment

Pfizer Inc. (NYSE: PFE)today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the company's ...
Fierce Biotech

Racing BMS and J&J, Bayer links asundexian to 26% stroke reduction to unblock path to FDA

Bayer has linked asundexian to a 26% reduction in stroke in a phase 3 study, setting the bar for Bristol Myers Squibb and ...

Cereno Scientific AB: Cereno Scientific broadens development focus for CS014 to pulmonary hypertension associated with interstitial lung disease

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that ...